secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001628280-25-003753
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease
--------------------------------------------------------------------------------

- High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.
- Comparison with propensity-matched natural history controls showed 5.4% overall LVEF improvement in high-dose group.
- Both doses were well-tolerated; no serious drug-related events reported among 41 enrolled DMD patients.
- Ifetroban holds FDA Orphan Drug and Rare Pediatric Disease Designations; first Phase 2 study for DMD heart disease.
- Company plans end of Phase 2 FDA meeting to discuss development path; potential first therapy for DMD cardiomyopathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025003753/0001628280-25-003753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025003753/cpix-20250204.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-003753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer